• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

CVS Hit One Out of the Park, Here's My Plan

I like the name, and I like the progress that CVS is making. This stock can go higher.
By STEPHEN GUILFOYLE
Nov 06, 2019 | 10:24 AM EST
Stocks quotes in this article: CVS

Even New York Mets fans appreciate the prolific home run call of the crosstown rival Yankees radio play by play announcer John Sterling. "It is high, it is far... it is ... GONE !! Baseball season may be over. Earnings season, not yet. CVS Health (CVS) hit one out of the park on Wednesday morning. For the third quarter, the firm posted adjusted EPS of $1.84 (6.3% growth) on revenue of $64.8 billion (+36.4% y/y). These headline numbers for both the top and bottom line easily beat expectations.

It gets better. Adjusted operating income screamed 48.9% higher to $3.9 billion. Breaking down the results by business segment paints a picture of overall corporate execution that goes well beyond what even those of us who have been invested in this name expected.

Pharmacy Services, the largest of CVS's business segments posted revenue of $36.018 billion, 6.5% growth from Q3 2018. The Retail side of the firm put a $21.466 billion print to the tape. This was good enough for 2.9% growth. There was however some contraction in operating income produced by this unit. The firm blames this at least partially on both a $205 million pre-tax loss on the sale of Onofre as well as the recording of a $96 million store rationalization charge. As for the Health Care Benefits segment, this is where the firm's late 2018 $69 billion acquisition of Aetna comes in. This group produced revenue of $17.181 billion that in turn provided adjusted operating income of $1.423 billion that almost entirely was not there last year at this time.

Turning The Tables

There are several items that I think stand out from the tables provide by the firm in the press release. For one, year to date net cash flow from operations is just huge, at $10.214 billion, up from $6.386 billion for the comparable nine months a year ago. The cash position has grown to just under $5.2 billion from just over $4 billion over the last nine months. Growth in total assets has grown 12.2% over that same period, while the firm's reliance upon "Goodwill" to balance accounts only increased 1.1%. Turning over to liabilities, while expenses are rising, it quickly becomes clear that the firm is making progress in reducing long-term debt, which for me had been on my mind.

Guidance

For the full year, as there is a quarter left on the clock, the firm increases it's own expectations for EPS to $6.97 to $7.05 versus consensus of $6.99. The new outlook increases the firm's guidance by eight cents on the low end and a nickel at the upper bound. The firm also confirmed guidance on cash flow from operations at a range of $10.1 billion to $10.6 billion. It seems that the nine month total would make that range clearly achievable should disaster be averted.

My Thoughts

My reasons for being in this name in the first place had been an expected improvement in profitability as the Aetna acquisition is integrated into the firm, as well as the annual $2 dividend (yielding just under 3% at these levels.) My concerns have been balance sheet management, and political risk. The firm is obviously working on the balance sheet.

That said, there remains a certain amount of swirling risk emanating from both sides of the aisle in Washington. From the right, there has been an on again, off again effort to target pharmacy benefit management firms, while from the left, "Medicare for all" would be an outright disaster for firms like this, not to mention the entire economy.

The Chart

In the aftermath of these earnings, the shares appear to be not only testing the upper trend line of our Pitchfork model, but breaking above a 61.8% retracement of the December through March selloff. Relative Strength appears to be at possibly overbought levels.

My Plan

I have a very large winner on my hands here. At $70, I am looking at a gain of just less than 30% for this name. My target price for this name had been $70 coming in, so I have to, by my own code of discipline, take some action. I will be a seller today, not a buyer.

I like the name, and I like the progress that CVS is making. This stock can go higher. I am still deciding whether or not I take my football and go home, or I leave something in place. Sometimes, one has to ring the register. For me, this is that day.

(CVS Health is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells CVS? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long CVS equity.

TAGS: Earnings | Investing | Stocks | Technical Analysis | Trading | Consumer | Healthcare | Pharmaceuticals

More from Investing

Navigating the Cycles of the Market

James "Rev Shark" DePorre
Apr 17, 2021 10:00 AM EDT

How Recency Bias and the Pareto Principle impact your trading decisions.

Netflix Reports Earnings on Tuesday: 5 Important Things to Watch

Eric Jhonsa
Apr 17, 2021 8:00 AM EDT

Along with its total subscriber adds, keep an eye on Netflix's regional growth rates, as well as its free cash flow guidance and content spending outlook.

Market Indices Continue to Hide Crazy Rotational Action

James "Rev Shark" DePorre
Apr 16, 2021 4:41 PM EDT

Fundamentals and valuations are secondary to shifting money into certain sectors.

Is the Market Wrong on Bank of America? Here's What the Charts Say

Bruce Kamich
Apr 16, 2021 2:21 PM EDT

Let's check in again on BAC after its latest earnings.

Liquid Media Group Is a Hidden Gem

Timothy Collins
Apr 16, 2021 1:33 PM EDT

With the options open, I believe the near-term puts offer an attractive play.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:05 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How recency bias and the Pareto Principle impact y...
  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login